EverHint – Momentum Swing — Volatile High Beta for Apr 14, 2026 – 8 Signals – Healthcare Leads (3)

What This Signal Is (Quick)

Volatile High Beta is a momentum swing trading strategy focused on High volatility stocks (60%+) - for risk-tolerant traders.

Signal Type: Breakout (momentum continuation)

What Makes This Signal:

• Stock showing strong momentum near or at highs
• Increased volume confirms institutional interest
• Breaking out or consolidating near resistance
• High volatility stocks (60%+) - for risk-tolerant traders

Ideal For: Risk-tolerant traders comfortable with high volatility and large price swings

Key Criteria:

• Strong RSI momentum (configurable thresholds)

• Volume surge above average

• Price momentum confirmation

• Minimum ADV: $25M+ (varies by variant)

• Earnings buffer: 7 days pre/post earnings

• Variant-specific filters applied

Holding Period: 1-4 weeks
Risk Level: Medium-High

How We Ranked Today

Ranked by composite momentum score (higher = stronger momentum)

📊 Momentum Swing — Volatile High Beta Signals (8 Total)

Ranked by score:

Field Notes

Sector concentration: Healthcare (3), Technology (2), Communication Services (1)

Insider selling: LWLG (Lightwave Logic, Inc., $-448K), TVTX (Travere Therapeutics, Inc., $-4.7M), SYRE (Spyre Therapeutics, Inc., $-1.5M)

Data coverage: 62.5% insider, 12.5% congressional (1 older/1y), 100.0% earnings, 87.5% analyst, 37.5% news

Peer Analysis

Understanding how these stocks relate to their industry peers:

ECG (Everus Construction Group, Inc.): Leads 10 peers: GVA ($126.98, -0.2%), AGX ($603.91, +0.9%), POWL ($234.42, +2.4%), BCO ($106.66, -0.2%), KBR ($36.36, -1.4%) | Peer of: ACA ($114.24, -0.2%), AGX ($603.91, +0.9%), ALK ($42.62, +6.6%) and 13 more

TVTX (Travere Therapeutics, Inc.): Leads 10 peers: CGON ($67.28, -0.6%), TARS ($73.81, +1.6%), CELC ($120.85, +0.4%), XENE ($59.35, +1.3%), CNTA ($39.59, +0.1%) | Peer of: ARQT ($25.09, +4.0%), CELC ($120.85, +0.4%), CGON ($67.28, -0.6%) and 9 more

LWLG (Lightwave Logic, Inc.): Leads 9 peers: GPRE ($15.39, -1.8%), GEVO ($2.00, -1.5%), KRO ($6.50, -1.8%), KOP ($38.44, +0.1%), WLKP ($22.60, -0.2%) | Peer of: CMCL ($25.79, +1.6%), CPAC ($10.78, -0.4%), GAU ($2.66) and 10 more

CLS (Celestica Inc.): Leads 9 peers: GRMN ($264.47, +1.1%), KEYS ($330.46, -0.2%), FICO ($1007.28, +0.6%), NOK ($10.35, -0.2%), FLEX ($80.14, +2.3%) | Peer of: EA ($202.85, +0.1%), FICO ($1007.28, +0.6%), GLW ($172.77, -1.3%) and 5 more

SYRE (Spyre Therapeutics, Inc.): Leads 10 peers: PHVS ($28.68, +2.9%), IMNM ($22.90, +1.2%), WVE ($7.39, +1.8%), NTLA ($14.78, +3.6%), ZYME ($26.98, +3.1%) | Peer of: ABCL ($3.76, +2.7%), ARDX ($6.33), AZTA ($24.26, +4.0%) and 12 more

ICHR (Ichor Holdings, Ltd.): Leads 10 peers: SKYT ($31.39, +7.9%), AEHR ($74.38, +3.8%), AOSL ($30.38, +10.9%), IMOS ($41.05, +0.3%), LAES ($2.59, +21.0%) | Peer of: AEHR ($74.38, +3.8%), AOSL ($30.38, +10.9%), CEVA ($21.47, +2.7%) and 4 more

GSAT (Globalstar, Inc.): Leads 6 peers: TKC ($6.42, +0.2%), TDS ($45.49, +0.5%), PHI ($20.65, +0.9%), LUMN ($7.80, +0.1%), MSGS ($339.74, +2.6%) | Peer of: MSGS ($339.74, +2.6%), NXST ($194.11, +5.3%), TKC ($6.42, +0.2%)

RVMD (Revolution Medicines, Inc.): Leads 9 peers: BBIO ($77.93, +0.1%), IONS ($76.76, +2.4%), EXEL ($45.86, +2.0%), MRNA ($52.84, +4.3%), BMRN ($55.47, +1.1%) | Peer of: ASND ($249.84, +0.5%), BBIO ($77.93, +0.1%), BMRN ($55.47, +1.1%) and 13 more

Congressional Activity

CLS (Celestica Inc.) 🟢 Bullish (1y)

• 1 purchase by 1 member
• Top buyer: Hou. Cleo Fields (LA) - 1 transaction ($15,001 - $50,000)

Recent Headlines

LWLG (Lightwave Logic, Inc.)

• Why Is Lightwave Logic Stock Charging Higher On Monday? (source)
• A Lightwave Logic (LWLG) Insider Sold 20,000 Shares After a Huge Run Up (source)
• Siraj Nour El-Ahmadi Sells 54,536 Shares of Lightwave Logic (NASDAQ:LWLG) Stock (source)
• Lightwave Logic Director Sells 9,000 Shares -- But Context Is Crucial (source)

RVMD (Revolution Medicines, Inc.)

• Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway (source)
• RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data (source)
• Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes (source)
• Revolution Medicines (RVMD) Hits All-Time Highs After Groundbreaking Cancer Trial Results (source)
• How This Biotech Stock Skirted Today's Selloff (source)
• Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough (source)
• Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo (source)
• Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial (source)
• This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success. (source)
• Stock Market Live April 13: S&P 500 (SPY) Back in the Red as Oil Gushes Higher (source)
• Revolution Medicines' experimental cancer pill helps improve survival in late-stage study (source)
• Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial (source)
• Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer (source)

TVTX (Travere Therapeutics, Inc.)

• FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients (source)
• Travere Therapeutics Stock Skyrockets On FDA Approval (source)
• Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript (source)
• US FDA expands approval for Travere Therapeutics' drug for rare kidney disease (source)
• Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS (source)
• Roy Baynes Sells 10,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock (source)
• Aberdeen Group plc Trims Holdings in Travere Therapeutics, Inc. $TVTX (source)

Market Context

Broad market indices advanced on the session, with the Nasdaq leading gains at +1.94%, followed by the S&P 500 at +1.17% and the Dow at +0.66%. This upward trend signals strong risk appetite, favoring momentum swing strategies that target volatile high beta names. These stocks, which amplify broader market moves, stand to benefit from the prevailing bullish momentum, potentially delivering amplified intraday swings as traders chase short-term trends.

The VIX declined sharply by 3.97% to 18.36, reflecting contracting volatility and a calmer trading environment. For volatile high beta plays, this moderation tempers extreme intraday fluctuations, reducing whipsaw risks while still supporting swing opportunities in a risk-on backdrop. Lower volatility enhances signal reliability by filtering out noise, allowing momentum setups to unfold more predictably amid the indices' positive trajectory.

Healthcare emerges as the top sector for the eight signals, hinting at rotation toward resilient areas amid the rally. In this context, high beta healthcare momentum trades could capture sector-specific swings, bolstered by overall market strength but insulated from broader volatility compression. Traders should monitor for sustained risk appetite to sustain these swings.

Vlad's Take (EverHint)

Today's signals: Strong sector concentration in Healthcare (3 signals) suggests sector-specific rotation. 5 signals showing insider selling warrant caution.

Sharing Call-to-Action

🚀 Support the project by liking, sharing, or subscribing — it helps more readers discover these signals.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/